Navigation Links
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Date:12/17/2007

Study Shows TYKERB Combination Reduced the Size of Brain Tumors Associated

with HER2-Positive Breast Cancer

SAN ANTONIO, Texas, Dec. 17 /PRNewswire/ -- GlaxoSmithKline announced today results from the extension arm of a Phase II study on its first-in-class, oral small molecule HER2 (ErbB2) kinase inhibitor, TYKERB(R) (lapatinib). In this study of 49 patients, the combination of TYKERB plus capecitabine (Xeloda(R)) showed a reduction in HER2-positive breast cancer that had spread to the brain and had progressed on TYKERB alone(1). Specifically, 20 percent of patients who received TYKERB plus capecitabine experienced at least a 50 percent volumetric reduction in measurable brain metastases; 37 percent of patients experienced a volumetric decrease that was greater than or equal to 20 percent. This is important because up to one-third of women with HER2-positive metastatic breast cancer may develop brain metastases during the course of their disease(2). Results of this and other important TYKERB studies are being presented at the 2007 San Antonio Breast Cancer Symposium in San Antonio, TX.

"As women live longer with advanced breast cancer, some are developing brain metastases that are getting worse despite standard treatments, such as radiation," said Nancy U. Lin, M.D., lead investigator and Instructor in Medicine, Dana-Farber Cancer Institute. "Very few medications have shown activity in the treatment of brain metastases, in particular HER2-positive metastatic breast cancer patients and therefore, these data are quite encouraging."

TYKERB, in combination with capecitabine, is approved in the United States for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab (Herceptin(R))(3). Additional studies are underway to learn the full potential of TYKERB for the prevention and treatment of brai
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... that develops and commercializes proprietary technologies and products for ... results for the fiscal first quarter ended December  31, ... Canadian dollars (CAD), unless otherwise stated. ... business from our existing customers and add to our ...
(Date:2/26/2015)... Feb. 26, 2015 DuPont Executive Vice President ... by key research advancements and product launches across the ... of America Merrill Lynch 2015 Global Agriculture Conference. ... building grain supplies the last two years, long-term demand ... pace of the last decade, when demand for corn ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... PALO ALTO, Calif., Oct. 24 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... third quarter 2007 financial results on Tuesday, November 6, ... Pharmaceuticals,will host an investor conference call and live audio ... November 6, 2007, at 5:00 p.m.,Eastern Time/2:00 p.m. Pacific ...
... Environment Where Scientists Thrive and Science is ... ... year, Abbott (NYSE: ABT ) has been named among the top ... Science is at the center of Abbott,s broad base of businesses. To,enhance ...
... Leading US Spine Centers Committed to the IEP,s ... 24 Magnifi Group, considered by,many industry observers ... within the medical device and pharmaceutical industries,announced here ... annual,meeting, its intent to organize and develop real-time ...
Cached Biology Technology:Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 3Magnifi Group Demonstrates Industry's First Interactive Educational Program (IEP) for Spine Fellows 2
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Institutes for Health (NIH) have awarded $4.5 million to ... artificial pancreas system that will monitor and adapt to ... This collaboration between physicians and engineers aims to merge ... human behavior, physiology, and medical technology and ultimately ...
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2011.   Revenue for the third quarter of ... million in the same quarter last year. Net income for the ... share. These results compared to net income of $76,000, or $0.00 ...
... The Greenland ice sheet can experience extreme melting even when ... by Dr. Marco Tedesco, assistant professor in the Department of ... York. His findings suggest that glaciers could undergo a ... to halt. "We are finding that even if you ...
Cached Biology News:NIH awards group $4.5 million for smart artificial pancreas technology 2NIH awards group $4.5 million for smart artificial pancreas technology 3Aware, Inc. Reports Third Quarter 2011 Financial Results 2Aware, Inc. Reports Third Quarter 2011 Financial Results 3Aware, Inc. Reports Third Quarter 2011 Financial Results 4Aware, Inc. Reports Third Quarter 2011 Financial Results 5Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3
... series of vacuum concentrators/centrifugal evaporators offers a ... to rapid and safe concentration of heat-labile ... with oil-free or high vacuum pumps, a ... selection of rotors (eliminating sample loss by ...
...
... RC Standard MB (For small quantities of ... samples) of vacuum concentrator/centrifugal evaporator systems respond ... biochemistry for rapid and safe concentration of ... expanded with pumps, different of cold traps ...
... MBS Start up kit. Includes configured Laptop ... of 1 MultiBlock satellite thermal Cycler ... User friendly software. Store/track run ... heated lid. Outstanding uniformity. Advanced ...
Biology Products: